Unipolar Depression Clinical Trial
Official title:
Evaluation of Metacognitive Training for Depression (D-MCT) in Outpatient Psychiatric-psychotherapeutic Care: Randomized Controlled Trial
Verified date | September 2019 |
Source | Universitätsklinikum Hamburg-Eppendorf |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Aim of the current study is to investigate the acceptance and efficacy of Metacognitive Training for Depression (D-MCT) compared to cognitive remediation in outpatients with major depressive disorders in a randomized, controlled, assessor-blind, group trial.
Status | Completed |
Enrollment | 86 |
Est. completion date | September 24, 2019 |
Est. primary completion date | August 22, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - informed consent - age between 18 and 70 years - diagnosis of a single Episode or recurrent Major depressive disorder (MDD) or dysthymia (verified by the MINI) Exclusion Criteria: - lifetime psychotic symptoms (i.e., hallucinations, delusions, or mania), suicidality (Suicidal Behaviors Questionnaire-Revised = 7), intellectual disability (estimated IQ < 70) or dementia. |
Country | Name | City | State |
---|---|---|---|
Germany | Asklepios Klinik Nord-Ochsenzoll | Hamburg |
Lead Sponsor | Collaborator |
---|---|
Universitätsklinikum Hamburg-Eppendorf | Asklepios Kliniken Hamburg GmbH |
Germany,
Andrews G, Issakidis C, Sanderson K, Corry J, Lapsley H. Utilising survey data to inform public policy: comparison of the cost-effectiveness of treatment of ten mental disorders. Br J Psychiatry. 2004 Jun;184:526-33. — View Citation
Cuijpers P. Psychotherapies for adult depression: recent developments. Curr Opin Psychiatry. 2015 Jan;28(1):24-9. doi: 10.1097/YCO.0000000000000121. Review. — View Citation
Fernandez E, Salem D, Swift JK, Ramtahal N. Meta-analysis of dropout from cognitive behavioral therapy: Magnitude, timing, and moderators. J Consult Clin Psychol. 2015 Dec;83(6):1108-22. doi: 10.1037/ccp0000044. Epub 2015 Aug 24. — View Citation
Jelinek L, Hauschildt M, Wittekind CE, Schneider BC, Kriston L, Moritz S. Efficacy of Metacognitive Training for Depression: A Randomized Controlled Trial. Psychother Psychosom. 2016;85(4):231-4. doi: 10.1159/000443699. Epub 2016 May 27. — View Citation
Jelinek L, Moritz S, Hauschildt M. Patients' perspectives on treatment with Metacognitive Training for Depression (D-MCT): Results on acceptability. J Affect Disord. 2017 Oct 15;221:17-24. doi: 10.1016/j.jad.2017.06.003. Epub 2017 Jun 7. — View Citation
Jelinek L, Otte C, Arlt S, & Hauschildt M. Denkverzerrungen erkennen und korrigieren: Eine Machbarkeitsstudie zum Metakognitiven Training bei Depressionen (D-MKT). [Identifying and correcting cognitive biases: A Pilot study on the Metacognitive Training for Depression (D-MCT)] Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 61, 247-254, 2013.
Mathews A, MacLeod C. Cognitive vulnerability to emotional disorders. Annu Rev Clin Psychol. 2005;1:167-95. Review. — View Citation
Moritz S, Veckenstedt R, Andreou C, Bohn F, Hottenrott B, Leighton L, Köther U, Woodward TS, Treszl A, Menon M, Schneider BC, Pfueller U, Roesch-Ely D. Sustained and "sleeper" effects of group metacognitive training for schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2014 Oct;71(10):1103-11. doi: 10.1001/jamapsychiatry.2014.1038. — View Citation
Vittengl JR, Clark LA, Dunn TW, Jarrett RB. Reducing relapse and recurrence in unipolar depression: a comparative meta-analysis of cognitive-behavioral therapy's effects. J Consult Clin Psychol. 2007 Jun;75(3):475-88. — View Citation
Wells, A., 2011. Metacognitive Therapy for anxiety and depression. The Guilford Press, New York.
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quick Inventory of Depressive Symptomatology (QIDS) | Primary outcome is change on the Quick Inventory of Depressive Symptomatology (QIDS) from baseline to follow-up (t0 - t2) | eight months from baseline (t0) to 6-months follow up (t2) | |
Secondary | Hamilton Depression Rating Scale | Change on the Hamilton Depression Rating Scale (HDRS, 17-item version) from baseline to follow-up (t0 - t2) | [Time Frame: eight months from baseline (t0) to 6-months follow up (t2)] | |
Secondary | Self-assessed depression | Change in self-assessed depression as measured by the Patient Health Questionnaire (PHQ-9) from baseline to follow-up (t0 to t2) | [Time Frame: eight months from baseline (t0) to 6-months follow up (t2)] | |
Secondary | Quick Inventory of Depressive Symptomatology (QIDS) | Change on the Quick Inventory of Depressive Symptomatology (QIDS) from baseline to post intervention assessment (t0 - t1) | from baseline (t0) to post intervention assessment at 8 weeks (t1) [time frame: 8 weeks] | |
Secondary | Hamilton Depression Rating Scale | Change on the Hamilton Depression Rating Scale from baseline to post intervention assessment (t0 - t1) | from baseline (t0) to post intervention assessment at 8 weeks (t1) [time frame: 8 weeks] | |
Secondary | Patient Health Questionnaire (PHQ-9) | Change on the Patient Health Questionnaire (PHQ-9) from baseline to post intervention assessment (t0 - t1) | from baseline (t0) to post intervention assessment at 8 weeks (t1) [time frame: 8 weeks] | |
Secondary | Dysfunctional beliefs | Change in dysfunctional beliefs as measured by the Dysfunctional Attitude Scale (DAS) from baseline to follow-up (t0 to t2) | eight months from baseline (t0) to 6-months follow up (t2 | |
Secondary | Quality of life | Change in quality of life as measured by the World Health Organization Quality of Life Assessment (WHOQOL-BREF) from baseline to follow-up (t0 to t2) | eight months from baseline (t0) to 6-months follow up (t2) | |
Secondary | Dysfunctional metacognitive beliefs | Change in metacognitive beliefs as measured by the Metacognitions Questionnaire (MCQ-30) from baseline to follow-up (t0 to t2) | eight months from baseline (t0) to 6-months follow up (t2) | |
Secondary | Rumination | Rumination measured by the Ruminative Response Scale (RRS) from baseline to follow-up (t0 to t2) | eight months from baseline (t0) to 6-months follow up (t2) | |
Secondary | Self-esteem | Change in self-esteem as measured by the Rosenberg Self-Esteem Scale (RSE) from from baseline to follow-up (t0 to t2) | eight months from baseline (t0) to 6-months follow up (t2) | |
Secondary | Remission rate | Remission rate at T2 as measured by the Hamilton Depression Rating Scale (HDRS score = 8) | eight months from baseline (t0) to 6-months follow up (t2) | |
Secondary | Information processing | Information processing as measured by the Trail-Making Test A (TMT-A) from baseline to post treatment assessment (t0 to t1) | from baseline (t0) to post intervention assessment at 8 weeks (t1) [time frame: 8 weeks] | |
Secondary | Subjective appraisal of the training | Subjective appraisal of the training after each session as well as at post treatment and follow up assessment (for questionnaire see Jelinek et al., 2017) | each week (session data) [time frame: 8 weeks] and six months from post treatment assessment (t1) to 6 months follow up (t1 to t2) [time frame: 6 months] | |
Secondary | Executive functioning | Executive functions as measured by the Trail-Making Test B (TMT-B) from baseline to post treatment assessment (t0 to t1) | from baseline (t0) to post intervention assessment at 8 weeks (t1) [time frame: 8 weeks] | |
Secondary | Verbal memory | Memory functioning as measured by Rivermead Behavioral Memory Test from baseline to post treatment assessment (t0 to t1) | from baseline (t0) to post intervention assessment at 8 weeks (t1) [time frame: 8 weeks] |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03256162 -
Ketamine as an Adjunctive Therapy for Major Depression
|
Phase 1 | |
Recruiting |
NCT05570110 -
Enoxolone in Major Depression - Biomarker-outcome Relationship
|
Phase 1/Phase 2 | |
Completed |
NCT02530164 -
Transcranial Direct Current Stimulation (tDCS) As Treatment for Major Depression
|
N/A | |
Completed |
NCT00964054 -
Depression Outcomes Study of Exercise
|
Phase 1 | |
Completed |
NCT01447602 -
A Clinical Trial of IPT-A to Prevent Suicide in Depressed Adolescents With Suicidal Behavior
|
Phase 3 | |
Completed |
NCT00517387 -
The Effects of Quetiapine XR on Cognition, Mood and Anxiety Symptoms in SSRI-Resistant Unipolar Depression
|
Phase 3 | |
Recruiting |
NCT04939649 -
Ketamine as an Adjunctive Therapy for Major Depression (2)
|
Phase 3 | |
Recruiting |
NCT05894980 -
How to Reduce Suicidal Thoughts and Impulsivity in Depression
|
N/A | |
Terminated |
NCT04712968 -
Efficacy of Daylight as Adjunctive Treatment in Patients With Depression
|
N/A | |
Enrolling by invitation |
NCT04717921 -
Assesment of Retinal Nerve Fiber Layer in First Episode Depressive Patients Using Selective Serotonin Reuptake Inhibitor
|
||
Recruiting |
NCT03358056 -
Effects of Mindfulness Based Cognitive Therapy on Emotional Processing
|
N/A | |
Recruiting |
NCT03711019 -
Efficacy of Convulsive Therapies During Continuation
|
N/A | |
Completed |
NCT02104232 -
Thinking Healthy Program - Peer Delivered, India (THPP-I)
|
N/A | |
Completed |
NCT02111915 -
Thinking Healthy Program - Peer Delivered (Pakistan)
|
N/A | |
Terminated |
NCT01219686 -
EScitalopram PIndolol ONset of Action
|
Phase 2/Phase 3 | |
Completed |
NCT00158990 -
Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.
|
Phase 3 | |
Completed |
NCT01049347 -
Amitriptyline and Paroxetine Treatment of Major Depression
|
Phase 3 | |
Completed |
NCT01880957 -
PET and MRI Brain Imaging of Bipolar Disorder
|
N/A | |
Completed |
NCT04420793 -
Voice Changes During ECT
|
||
Not yet recruiting |
NCT01694030 -
Effects of Repeated Attachment Security Priming on Depressed Mood: a Clinical Study
|
Phase 1 |